Core Insights - BioMark Diagnostics has secured patents in China and Japan for its liquid biopsy technology aimed at early lung cancer detection, enhancing its intellectual property and commercial strategy in these key markets [1][2][3] Company Overview - BioMark Diagnostics Inc. specializes in developing liquid biopsy tests that utilize metabolomics and machine learning for early cancer detection, enabling earlier diagnosis and improved patient outcomes [4] Technology and Market Potential - The newly granted patents cover a platform that measures specific metabolite biomarkers, demonstrating a sensitivity of over 90% for early-stage lung cancer, which can lead to faster and more actionable clinical results [2][3] - The liquid biopsy market in China is projected to exceed US$670 million by 2030, while Japan's market is expected to surpass US$912 million, both showing robust double-digit growth driven by national screening policies and advanced diagnostics [3] Strategic Importance - Securing patents in China and Japan is seen as a transformational milestone for BioMark, positioning the company for significant commercial and clinical leadership, as well as opportunities for expansion, technology licensing, and strategic partnerships [3]

Core Insights - The article presents new data from a proof-of-concept study on the detection of circulating tumor cells (CTCs) in glioblastoma patients, highlighting the effectiveness of the Parsortix label-free methodology [1] Company Overview - ANGLE plc is a leading company in the liquid biopsy sector, specializing in innovative CTC solutions for research, drug development, and clinical oncology [1] Study Details - The study involved 15 newly diagnosed, treatment-naïve glioblastoma (GBM) patients, with blood samples processed using the Parsortix® system and CellKeep™ slides [1]